Unlocking the True Potential of CRISPR Cas9 Gene Editing!
Europe's #1 event for addressing CRISPR's application challenges
AstraZeneca and Novartis have turned to CRISPR for drug discovery, have you?
2015 has seen an increasing percentage of pharmaceutical companies implement CRISPR technologies into their drug discovery plans.
Earlier this year Novartis' Institute for BioMedical Research (NIBR) President Mark Fishman stated "we have glimpsed the power of CRISPR tools in our scientific programs in NIBR, and it is now time to explore how to safely extend this powerful technology to the clinic."*
AstraZeneca have announced four research collaborations aimed at harnessing the power of CRISPR, and GlaxoSmithKline is leading a $64 million investment for CRISPR Therapeutics.
There is no doubt about it, CRISPR is rapidly changing the way diseases are researched, and will soon revolutionise the way they are treated.
Whether you are already underway with using CRISPR in your research, or are considering implementing the technology, this conference will provide you with all the information you need to harness CRISPR’s true potential.
In preparation for the event, we invite you to take part in a short online study to evaluate current and future usage of CRISPR for various applications. The results will then be provided to you, so that you can compare your responses to those of your peers. Please click this link to go to the survey, or copy and paste the link www.surveymonkey.com/r/CRISPRsurvey into your internet browser.
For the first time in Europe, Pharma IQ is bringing together key industry leaders to introduce you to the CRISPR revolution, and help you address the specificity, efficiency and delivery challenges preventing you from making the most of the CRISPR technology. Take a look at the agenda, view our full speaker line-up of CRISPR founders and industry-leading experts, or go straight ahead and book your place now.